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Abstract
Signal transducer and activator of transcription STAT5 and its upstream activating kinase JAK2 are essential mediators of
cytokine signaling. Their activity is normally tightly regulated and transient. However, constitutive activation of STAT5 is
found in numerous cancers and a driving force for malignant transformation. We describe here the identification of the
synthetic chalcone a-Br-29,3,4,49-tetramethoxychalcone (a-Br-TMC) as a novel JAK/STAT inhibitor. Using the non-
transformed IL-3-dependent B cell line Ba/F3 and its oncogenic derivative Ba/F3-1*6 expressing constitutively activated
STAT5, we show that a-Br-TMC targets the JAK/STAT pathway at multiple levels, inhibiting both JAK2 and STAT5
phosphorylation. Moreover, a-Br-TMC alters the mobility of STAT5A/B proteins in SDS-PAGE, indicating a change in their
post-translational modification state. These alterations correlate with a decreased association of STAT5 and RNA polymerase
II with STAT5 target genes in chromatin immunoprecipitation assays. Interestingly, expression of STAT5 target genes such as
Cis and c-Myc was differentially regulated by a-Br-TMC in normal and cancer cells. While both genes were inhibited in IL-3-
stimulated Ba/F3 cells, expression of the oncogene c-Myc was down-regulated and that of the tumor suppressor gene Cis
was up-regulated in transformed Ba/F3-1*6 cells. The synthetic chalcone a-Br-TMC might therefore represent a promising
novel anticancer agent for therapeutic intervention in STAT5-associated malignancies.
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Introduction
The signal transducer and activator of transcription STAT5 is a
key regulator of immune responses, cell proliferation, differenti-
ation, survival and oncogenesis [1,2]. STAT5 proteins normally
reside as latent transcription factors in the cytoplasm of
unstimulated cells. Following cytokine, growth factor or hormone
stimulation, the receptor-associated JAK2 tyrosine kinase gets
auto-phosphorylated (trans-phosphorylation) before it phosphory-
lates the receptor intracellular domain, creating docking sites for
STAT5, which is in turn phosphorylated by activated JAK2.
STAT5 phosphorylation allows its dimerization and translocation
into the nucleus where it binds to specific recognition sites, and
ultimately activates transcription of specific target genes (e.g. c-
Myc, Pim-1, Bcl-x, Cis) [1,3–5]. STAT5 activity is regulated
through multiple post-translational modifications [1,6–8] and
through interactions with cofactors, other transcription factors or
STAT5 itself (tetramerization) [1,9–15]. STAT5 activation under
physiological conditions is rapid and transient. Attenuation of the
STAT5 response is controlled mainly through dephosphorylation
by specific phosphatases (SHP-1) and a negative feedback loop
mediated by proteins of the SOCS family (CIS, SOCS-1/-3)
[16,17]. However, constitutively activated STAT5 (caSTAT5) has
been observed in a wide variety of human cancers, from
hematologic malignancies (leukemia, lymphoma, myeloma) to
solid tumors such as breast cancer, squamous cell carcinoma of the
head and neck (SCCHN) or melanoma [16–18]. Constitutive
activation of STAT5 directly contributes to oncogenesis, mainly
through the up-regulation of oncogenes driving cell proliferation
and survival (Bcl-x, c-Myc, Pim-1) [4,19–23], but also through the
down-regulation of tumor suppressor genes and inhibitors of the
pathway, such as SHP-1 and CIS/SOCS family members, via
epigenetic silencing [17,18,24–28].
Therefore, the JAK/STAT pathway in general and STAT5
proteins in particular represent attractive targets for therapeutic
intervention in human cancers [18,29–31]. Numerous inhibitors of
the Janus Kinase family members (JAK1, JAK2, JAK3, Tyk2, and
the JAK2V617F active mutant responsible for myeloproliferative
neoplasia) and of STAT5 have been described [30,32–45]. Most of
the JAK inhibitors are small molecules acting as tyrosine kinase
inhibitors by targeting their ATP-binding catalytic domain. The
JAK1/JAK2 inhibitor Ruxolitinib has been approved by the U.S.
Food and Drug Administration for the treatment of myelofibrosis
while several others are being currently evaluated in clinical trials
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for the treatment of various diseases [32,33]. Reported STAT5
inhibitors target STAT5 activity at multiple levels, from its
activation by phosphorylation to its DNA binding activity,
independently of upstream activating kinases [30,34,35,38,
39,45]. We were the first to show that deacetylase inhibitors such
as sodium butyrate, trichostatin A (TSA) or suberoylanilide
hydroxamic acid (SAHA) inhibit IL-3-mediated STAT5 transcrip-
tional activity in the mouse pro-B cell line Ba/F3 [46]. We
demonstrated that deacetylase inhibitors interfere neither with
STAT5 initial activation (phosphorylation or nuclear transloca-
tion) nor with STAT5 binding to DNA in vivo. Instead, these drugs
prevent the proper assembly of the basal transcription machinery
ultimately resulting in inhibition of transcription [46,47]. The
deacetylase inhibitor SAHA (Vorinostat) has been approved for
the treatment of cutaneous T cell lymphoma while many other
deacetylase inhibitors are currently evaluated in clinical trials for
the treatment of various types of cancers [48]. Therefore our
findings support the attractive possibility that this class of drugs
might be efficient in targeting STAT5-associated cancers.
Accordingly, tyrosine kinase inhibitor and deacetylase inhibitor
combination therapies have recently proven to be more effective in
the treatment of cancers with constitutive active STAT5 [49–53].
More recently, we turned to the identification of new types of
STAT5 inhibitors, with a particular focus on natural and synthetic
chalcones.
Chalcones, which are naturally abundant in fruits, vegetables
and spices, are a,b-unsaturated carbonyl compounds well known
for their multiple biological activities as antioxidant, antibacterial,
antifungal, anti-inflammatory and anticancer agents [54]. Natural
and synthetic chalcones have been shown to inhibit the function of
a variety of tyrosine kinases (JAKs, ERKs, Src) and transcription
factors (NF-kB, STAT3) implicated in the response to inflamma-
tion and the control of cell proliferation and survival [54–58]. We
therefore hypothesized that the JAK2/STAT5 signaling pathway
might be affected by chalcones. We previously described the
synthesis of a-X-29,3,4,49-tetramethoxychalcones (a-X-TMCs)
with different X substituents (X=H, F, Cl, Br, I, CN, Me, p-
NO2-C6H4, Ph, p-OMe-C6H4, NO2, CF3, COOEt, COOH) at
the a-position of the a,b-unsaturated carbonyl unit [59]. We
formerly showed that these a-X-TMCs have distinct electrophilic
reactivities [59–61] which correlate well with their anti-inflamma-
tory activity [59]. In this study, the ability of four a-X-TMCs (with
X=CN, Br, Cl, H) to regulate STAT5 function was investigated.
Five natural chalcones, namely 29-hydroxy-3,4,49-trimethoxychal-
cone (HTMC), 29,49-dihydroxy-3,4-dimethoxychalcone (DHDM
C), 29,3,49-trihydroxy-4-methoxychalcone (THMC), butein, and
isoliquiritigenin (ISL), as well as curcumin, another natural
product carrying two a,b-unsaturated carbonyl groups, were also
investigated (Figure 1A).
We describe here a-Br-29,3,4,49-tetramethoxychalcone (a-Br-
TMC) as a novel inhibitor of the STAT5 signaling pathway. We
show that a-Br-TMC inhibits both JAK2 and STAT5 phosphor-
ylation, leading to the inhibition of expression of downstream
STAT5-dependent and -independent genes in IL-3-stimulated
Ba/F3 cells. Moreover, a-Br-TMC alters the mobility of STAT5A
and STAT5B proteins in SDS-PAGE, both in cells expressing
regulated (Ba/F3) and constitutively active (Ba/F3-1*6 and K562)
STAT5, presumably reflecting a change in STAT5 post-transla-
tional modifications. Nevertheless, a-Br-TMC treatment affects
differentially STAT5 transcriptional activity in normal and cancer
cells. Altogether, this study identified a novel inhibitor of STAT5
signaling targeting both STAT5 and its upstream activating kinase




Chalcones were prepared by published procedures [59,60].
Dimethyl sulfoxide (DMSO), trichostatin A (TSA) and curcumin
were purchased from SIGMA (D2650, T8552 and B6938
respectively). Imatinib was from Cayman Chemical (No. 13139).
Compounds were dissolved in DMSO at a final concentration of
1 mM (TSA) or 100 mM (other compounds).
Thiol assay
Kinetic thiol assay for TSA (Biotrend BN0742) was performed
as described [60] using 500-fold excess cysteamine as a thiol
substrate and an incubation time of 48 hours. The presence of the
addition product was detected by liquid chromatography-mass
spectrometry (not shown). Second-order rate constants k2 values
for chalcones and curcumin are taken from the literature [59,60].
Cell lines and drug treatments
All cell lines were grown in RPMI 1640 (PAN-Biotech P04-
16500) supplemented with 10% heat-inactivated fetal calf serum
(FCS; PAN-Biotech), penicillin/streptomycin (PAN-Biotech)
(thereafter designated as RPMI-based medium) and cultivated at
37uC under 5% CO2 in a humidified incubator. K562 cells (a kind
gift from Daniela Ma¨nnel, University of Regensburg, Germany;
[62]) were maintained in RPMI-based medium. The non-
tumorigenic immortalized interleukin-3 (IL-3)-dependent mouse
pro-B cell line Ba/F3 (a kind gift from Jacqueline Marvel, IFR 128
BioSciences Gerland-Lyon Sud, France; [63]) was grown in
RPMI-based medium supplemented with 2 ng/mL rmIL-3
(ImmunoTools). The Ba/F3-1*6 cell line stably expressing the
constitutively active mouse STAT5A-1*6 mutant [64] was
generated according to German GenTSV (genetic engineering
safety regulations; authorization AZ.55.1-8791.7.52) by electropo-
rating Ba/F3 cells with a pcDNA3-based expression vector
allowing expression of a mSTAT5A-1*6-FLAG fusion protein.
Stably transfected cells were selected in IL-3-free medium in the
presence of 500 mg/mL G418 (PAA). Individual IL-3-independent
clones were isolated and characterized to verify mSTAT5A-1*6
transgene expression and constitutive activity, as originally
described [64]. Clone Ba/F3-1*6 F7 was used for this study. Cells
were maintained in RPMI-based medium supplemented with
500 mg/mL G418.
For cytokine stimulation of Ba/F3 cells, cells were washed twice
in RPMI 1640 and rested in RPMI-based medium for 12 hours
before addition of 5 ng/mL IL-3. Duration of IL-3 stimulation
was contingent upon the downstream assay, as indicated in the
figure legends. For chalcone and other inhibitor treatments, Ba/F3
cells were incubated with compounds or DMSO (vehicle) for 30
minutes prior to cytokine stimulation. Ba/F3-1*6 and K562 cells
were treated for 60–90 minutes with the various compounds or
DMSO (vehicle), as indicated. With the exception of cell viability
assays (see below), all experiments were performed in the presence
of equal amounts of DMSO.
Gene expression analysis by quantitative RT-PCR
Following inhibitor and cytokine treatments, cells were harvest-
ed, lysed in the iScript RT-qPCR sample preparation reagent
(170–8899, Bio-Rad Laboratories) and subjected to cDNA
synthesis using the iScript cDNA Synthesis kit (170–8891, Bio-
Rad Laboratories), following the manufacturer’s instructions.
Quantitative PCR was performed on a RotorGene Q (Qiagen)
with SYBR Green I and HotStarTaq (Qiagen). Data were
normalized to either S9 ribosomal mRNA (Ba/F3 and Ba/F3-
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1*6 cell lines) or human Lamin A/C (LMNA) mRNA (K562 cell
line), and expressed as relative mRNA levels, as previously
described [3,46,47]. Real-time PCR primers specific for the
following mouse (m) or human (h) cDNAs have been described: S9
(m), Cis (m), c-Myc (m/h), Pim-1 (m), Osm (m), c-Fos (m), Jun-B (m),
36b4 (m) and LMNA (h) [46,65]. Forward (fwd) and reverse (rev)
real-time PCR primers specific for human Cis cDNA were 59-
CTGCTGTGCATAGCCAAGACC-39 (fwd) and 59-GTGCCT-
TCTGGCATCTTCTGC-39 (rev), and for mouse Ho-1 cDNA
were 59-GCTGGTGATGGCTTCCTTGT-39 (fwd) and 59-
Figure 1. a-Br-TMC inhibits IL-3-mediated induction of STAT5-dependent and -independent genes in Ba/F3 cells. (A) Structure of the
natural and synthetic chalcones used in this study. Second-order rate constants k2 values of compounds obtained using cysteamine in TRIS-HCl buffer
pH 7.4: ethylene glycol 20:80 are taken from refs. [59,60]. (B) Ba/F3 cells were pre-treated 30 minutes with 0.2 mM (TSA) or 20 mM (all other
compounds) candidate inhibitors and stimulated 60 minutes with 5 ng/mL IL-3, as described in Materials and Methods. Following cell harvest,
expression of the STAT5 target gene Cis and of the housekeeping gene 36b4 were measured by quantitative RT-PCR, as described in Materials and
Methods. Together with TSA, a-Br-TMC was the only compound able to inhibit expression of the STAT5 target gene Cis. (C) Ba/F3 cells were pre-
treated 30 minutes with the indicated concentrations of TSA and a-Br-TMC and further stimulated with 5 ng/mL IL-3 for 30 minutes. Expression of
STAT5-dependent (Cis, Osm, c-Myc) and -independent (JunB, Ho-1, 36b4) genes was analyzed by quantitative RT-PCR. DMSO (vehicle) was adjusted to
0.02% final concentration in all conditions. Curcu., curcumin.
doi:10.1371/journal.pone.0090275.g001
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GGTTCTGCTTGTTGCGCTCT-39 (rev). Data shown are
representative of at least three independent experiments.
Cytotoxicity assays
WST-1 assays (11 644 807 001, Roche) were performed as
described in the manufacturer’s protocol. The tetrazolium salt
WST-1 is cleaved into the formazan dye by mitochondrial
dehydrogenase enzymes. Changes in metabolically active mito-
chondrial dehydrogenases as a result of TSA- or a-Br-TMC-
induced cytotoxicity was evaluated by measuring formazan dye
production upon incubation with the WST-1 reagent. Rested Ba/
F3 and growing Ba/F3-1*6 and K562 cells were pre-treated for 30
minutes with the indicated TSA and a-Br-TMC concentrations or
with DMSO (vehicle), as in our gene expression analysis
experiments. WST-1 reagent was added to the cells either alone
(Ba/F3-1*6, K562) or together with IL-3 (Ba/F3). Absorbance was
measured in a microplate reader (Mithras LB 940, Berthold
Technologies) at 450/620 nm after incubation at 37uC under 5%
CO2 in a humidified incubator for 90 minutes. This duration of
treatment was chosen as it is both optimal for the WST-1 assay
(not shown) and close to the maximal duration of inhibitor
treatment in our gene expression studies. A positive control for no
mitochondrial enzyme activity (1% Triton X-100) was included in
every experiment. Data are expressed as a percentage of
cytotoxicity relative to DMSO (vehicle). Small molecule inhibitor
treatment was carried out 2 to 3 times for each cell line, and the
WST-1 assay was performed in duplicate. Results of one
representative experiment are shown.
Cell viability assays
Equal cell numbers of growing Ba/F3, Ba/F3-1*6 and K562
cells were incubated for 24 and 48 hours in the presence of the
indicated TSA and a-Br-TMC concentrations. Since very low
DMSO concentrations were used (0.0005% to 0.01% final), no
DMSO vehicle control was included. The total number of living
and dead cells was evaluated by Trypan Blue exclusion. Viable cell
number, reflecting cell proliferation and survival, was plotted as a
function of time for each treatment. Data shown are representative
of at least three independent experiments.
Quantitative chromatin immunoprecipitation (ChIP)
assays
Chromatin immunoprecipitation was performed as previously
described [3,46,47] with the following modifications: sonication
was performed on a BRANSON SONIFIER 250 and cell samples
were subjected to 6 pulses of 60 seconds each (output control: 5;
duty cycle: 60%); Immunoprecipitated genomic DNA was purified
on a Nucleospin clean-up column (740609, Macherey-Nagel)
following their recommended protocol for SDS-containing sam-
ples. STAT5 and RNA polymerase II antibodies, as well as real-
time PCR primers specific for the STAT5 binding sites of the
mouse Cis gene and for the transcription start site (tss) of the mouse
Cis and Osm genes, have been described [46]. Real-time PCR
primers specific for the mouse Osm STAT5 binding sites (2184/
2122 relative to tss) were 59-CATCATCCTTGGGCGTGG-
GGC-39 (fwd) and 59-CGCTCCTCCTCCCGTTTTCTTCG-39
(rev). Data shown are representative of at least three independent
experiments.
Protein analysis
Whole-cell Brij protein lysis, nuclear and cytosolic protein
extractions, and Western-blot analyses were performed as
described [46,65]. Antibodies used for detection of the respective
proteins and their relevant dilutions were: pSTAT5 (#9351, Cell
Signaling Technology; 1:1000), STAT5A (L-20, sc-1081, Santa-
Cruz Biotechnology; 1:1000), STAT5B (G-2, sc-1656, Santa-Cruz
Biotechnology; 1:200), STAT5A+B (C-17, sc-835, Santa-Cruz
Biotechnology; 1:1000), pJAK2 (Cell Signaling Technology,
#3771; 1:200), JAK2 (#3230, Cell Signaling Technology;
1:500), a-tubulin (DM1A, sc-32293, Santa-Cruz Biotechnology;
1:200), Anti-Rabbit IgG-Peroxidase (SIGMA A0545; 1:10,000),
Anti-Mouse IgG-Peroxidase (SIGMA A8924; 1:10,000). Apparent
molecular weight of detected proteins was as predicted by the
antibody manufacturers, i.e. 125 kDa for JAK2, 90 kDa for
STAT5 (with STAT5A running slightly slower than STAT5B in
SDS-PAGE, as confirmed by the STAT5A+B immunoblots) and
55 kDa for a-tubulin. Chemoluminescence detection was
performed using Amersham ECL Prime (RPN2232, GE Health-
care Life Sciences) or SuperSignal West Femto (34095, Thermo
Fisher Scientific) for weaker signals, and images were captured on
an ImageQuant LAS 4000 mini imaging system (GE Healthcare
Life Sciences). Immunoblots shown are representative of at least
three independent experiments.
Results
The a-Br-chalcone a-Br-TMC inhibits expression of IL-3-
induced STAT5-dependent and -independent genes in
mouse Ba/F3 cells
In our initial screening for potential STAT5 inhibitors we chose
a variety of natural and synthetic chalcones characterized towards
their chemical reactivity in Michael additions with thiols. The
respective second-order rate constants (k2) of a-X-TMCs (with
X=CN, Br, Cl, H) using cysteamine as substrate [59–61] revealed
differences of more than four orders of magnitude (Figure 1A),
pointing to large variations in electrophilic reactivity. We also
included the natural product curcumin, which is a weak
electrophile (k2 = 0.0660 M
21s21) [60], and the synthetic lysine
deacetylase inhibitor trichostatin A (TSA), which serves as a
reference compound for STAT5 inhibition [46,47]. A kinetic thiol
assay on TSA, which contains an a,b,c,d-unsaturated carbonyl
unit, revealed very low amounts of the expected thiol adduct by
mass spectrometry after 48 hours incubation with 500-fold excess
of cysteamine (data not shown). This indicates that TSA main
activity is not based on an electrophilic behavior, as anticipated
from its electron-rich carbonyl functionality.
To identify novel inhibitors of the STAT5 signaling pathway,
these ten natural and synthetic chalcones as well as curcumin were
tested for their ability to suppress IL-3-mediated induction of the
STAT5 target gene Cis. The gene Cis was selected for the initial
screen as it is a well characterized STAT5-dependent gene
[3,46,47,66] and a potential therapeutic target in STAT5-
associated cancers [67].
Ba/F3 cells withdrawn from IL-3 for 12 hours (STAT5
pathway turned off) were pre-treated for 30 minutes with
0.2 mM TSA or with 20 mM natural and synthetic chalcones or
curcumin, before being stimulated with IL-3 for 1 hour
(Figure 1B). Out of the 10 compounds tested, one (a-Br-
29,3,4,49-tetramethoxychalcone thereafter called a-Br-TMC) ex-
erted an 80% inhibition of IL-3-mediated induction of Cis
expression, comparable to that exerted by TSA, while the
housekeeping gene 36b4 remained unaffected (Figure 1B). In the
following experiments, we therefore focused on characterizing a-
Br-TMC activity, using TSA as a reference inhibitory compound.
First, we ensured the absence of a-Br-TMC-mediated cytotox-
icity in the investigated time frame (up to 90 minutes treatment) in
IL-3-stimulated Ba/F3 cells (Figure 2A). No cytotoxicity was
Inhibition of JAK2 and STAT5 by a a-Br-Chalcone
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detected up to 10 mM a-Br-TMC. However, strong cytotoxicity
was evidenced at an a-Br-TMC concentration of 100 mM
(Figure 2A). Thus a-Br-TMC was further used at concentrations
not above 10 mM. We also investigated the long term effect of a-
Br-TMC treatment on cell proliferation and survival of IL-3-
growing Ba/F3 cells (Figure 2B). Similarly to TSA, a-Br-TMC
impaired cell growth and viability in a dose-dependent manner.
Ba/F3 cells cultured in 5 mM a-Br-TMC for 24 and 48 hours
stopped dividing and died, while cells grown in 0.5 mM a-Br-TMC
showed limited cell death and reduced cell proliferation (Figure 2B
and data not shown).
We then analyzed expression of a series of STAT5 target genes
(Cis, Osm, c-Myc) as well as STAT5-independent genes (JunB, Ho-1,
36b4) in dose-response experiments using 0.4 to 10 mM a-Br-
TMC. Rested Ba/F3 cells were incubated 30 minutes with the
respective compounds and stimulated with IL-3 for 30 minutes
(Figure 1C). Induction of all three STAT5 target genes was
inhibited by a-Br-TMC in a dose-dependent manner. In addition,
the IL-3-inducible STAT5-independent gene JunB, while unaf-
fected by TSA as expected [46], was also inhibited by a-Br-TMC
in a dose-dependent manner (Figure 1C). It is thought that JunB is
induced through the JAK2/MAPK pathway [68,69], therefore
suggesting that a-Br-TMC is targeting the upstream JAK/STAT
pathway rather than STAT5 itself. a-Br-TMC was shown to up-
regulate the Nrf2-dependent anti-inflammatory HO-1 protein
levels in the mouse macrophage cell line RAW264.7 [59]. In Ba/
F3 cells however, although Ho-1 gene expression was slightly up-
regulated by IL-3 and TSA, no dose-dependent effect of a-Br-
TMC was observed (Figure 1C), suggesting that the Nrf2-
dependent anti-inflammatory response pathway is - if at all - only
modestly activated and not influenced by a-Br-TMC. In contrast
to IL-3-regulated genes, expression of the control gene 36b4
remained unaffected by a-Br-TMC treatment (Figure 1C), further
supporting specificity of action.
Together, these gene expression data suggest that a-Br-TMC
might target the JAK/STAT pathway for inhibition. We therefore
monitored the effect of a-Br-TMC on STAT5 and JAK2 protein
phosphorylation.
a-Br-TMC inhibits both JAK2 and STAT5 phosphorylation
STAT5 proteins are expressed in two forms, STAT5A and
STAT5B, with both redundant and unique functions and encoded
by two related genes. STAT5A and STAT5B exhibit 91% identity
in their amino acid sequence, the C-terminal transactivation
domain being most divergent [3]. STAT5 phosphorylation in IL-
3-stimulated Ba/F3 cells pre-treated with either 0.2 mM TSA or
0.4 to 10 mM a-Br-TMC was investigated by Western-blot using a
phospho-STAT5-specific antibody (pSTAT5) (Figure 3A). IL-3-
induced STAT5 phosphorylation was not affected by TSA, in
agreement with our previous report [46]. By contrast, IL-3-
induced STAT5 phosphorylation was decreased by a-Br-TMC in
a dose-dependent manner. Interestingly, both STAT5A and
STAT5B proteins showed a dose-dependent downward mobility
shift in SDS-PAGE, with STAT5B being more affected than
STAT5A (Figure 3A). This mobility shift suggests that a-Br-TMC
induces a protein modification targeting both STAT5 proteins.
Analysis of cytosolic and nuclear fractions of unstimulated and
stimulated a-Br-TMC-treated cells, revealed that this a-Br-TMC-
Figure 2. Effect of a-Br-TMC on cytotoxicity and viability of normal (Ba/F3) and transformed (Ba/F3-1*6, K562) cells. (A) Cells were
pre-treated 30 minutes with 0.001, 0.01, 0.1 and 1 mM TSA or with 0.1, 1, 10 and 100 mM a-Br-TMC before starting the WST-1 assay. IL-3 (5 ng/mL) was
added to rested Ba/F3 cells at the same time as the WST-1 reagent to mimic the IL-3 stimulation conditions used in other assays. DMSO (vehicle)
concentration was adjusted to 0.1% final in all conditions. OD measurement was performed after 90 minutes incubation with the WST-1 reagent, and
the percentage of cytotoxicity was normalized to the vehicle control. (B) Growing Ba/F3, Ba/F3-1*6 and K562 cells were incubated for 24 and
48 hours in the presence of the indicated concentrations of TSA and a-Br-TMC. Cell viability was measured by Trypan Blue exclusion assay.
doi:10.1371/journal.pone.0090275.g002
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mediated protein modification is taking place in the cytoplasm of
unstimulated cells (Figure 3B) and hence is IL-3-independent.
Analysis of cytosolic and nuclear fractions of a-Br-TMC-treated
cells also confirmed that STAT5 phosphorylation and nuclear
translocation are reduced (Figure 3B), thus supporting the idea
that STAT5 activation is impaired upon a-Br-TMC treatment. Of
note, the detection of shifted bands by the pSTAT5 antibody in
the cytosolic and nuclear fractions of a-Br-TMC-treated IL-3-
stimulated cells, suggests that the modified STAT5 protein can be
to some extent phosphorylated at the expected tyrosine residue
(Y694/699 in STAT5A/B respectively) and translocated into the
nucleus.
STAT5 activation by IL-3 relies on the initial activation of the
cellular tyrosine kinase JAK2 [70]. Our gene expression data
revealing an inhibitory effect of a-Br-TMC on expression of the
JAK2/MAPK-dependent JunB gene (Figure 1C) suggest that a-Br-
TMC might also target the upstream JAK2 tyrosine kinase. We
therefore investigated whether IL-3-induced phosphorylation of
JAK2 was inhibited by a-Br-TMC. Ba/F3 cells were treated as
before with 10 mM a-Br-TMC and briefly stimulated with IL-3 to
analyze JAK2 phosphorylation by Western-blot using a pJAK2-
specific antibody (Figure 3C). Following a-Br-TMC treatment,
JAK2 phosphorylation was strongly diminished. By contrast to
STAT5A and STAT5B proteins, JAK2 protein mobility was not
affected by a-Br-TMC (Figure 3C).
Altogether, these experiments demonstrated that the a-Br-
chalcone a-Br-TMC has the ability to inhibit the JAK/STAT
pathway at multiple levels, by targeting both JAK2 and STAT5
proteins in IL-3-stimulated Ba/F3 cells.
a-Br-TMC inhibits STAT5-mediated transcriptional activity
The effect of a-Br-TMC on STAT5 transcriptional activity was
further investigated by chromatin immunoprecipitation (ChIP).
We previously showed that the deacetylase inhibitor TSA inhibits
STAT5-mediated transcription at a step subsequent to STAT5
binding to its target genes by preventing recruitment of the
transcriptional machinery [46]. STAT5 and RNA polymerase II
ChIP assays were performed on TSA- and a-Br-TMC-treated Ba/
F3 cells and protein recruitment to the mouse Cis and Osm
promoters was examined (Figure 4). In agreement with our former
report [46], RNA polymerase II recruitment to the Cis and Osm
promoters was abrogated upon TSA treatment, without notably
affecting STAT5 DNA binding activity. Although the level of
nuclear pSTAT5 was strongly reduced in a-Br-TMC-treated cells
(Figure 3B), the proportion of STAT5 bound to the Cis and Osm
promoters was only moderately affected (20% and 58% reduced
respectively; Figure 4A and B). This indicates that the nuclear pool
of STAT5 proteins in a-Br-TMC-treated Ba/F3 cells might still
support efficient binding to target sites. On the other hand, in
correlation with the reduced Cis and Osm mRNA levels (Figure 1),
recruitment of the RNA polymerase II to the Cis and Osm
transcription start sites was markedly impaired (55% and 94%
respectively; Figure 4A and B), pointing to an a-Br-TMC-
mediated transcriptional inhibition of the Cis and Osm STAT5
target genes in Ba/F3 cells.
a-Br-TMC differentially affects JAK/STAT signaling in cells
transformed by constitutively active STAT5
We showed that a-Br-TMC can inhibit IL-3-mediated JAK2
and STAT5 activation in normal mouse Ba/F3 cells. We next
addressed whether a-Br-TMC can also hinder JAK/STAT
activity in cancer cells exhibiting constitutive activation of STAT5.
For this purpose, we compared gene expression patterns of normal
Ba/F3 cells to those of transformed Ba/F3-1*6 and K562 cells.
Ba/F3-1*6 cells stably express a mutant form of mouse
STAT5A (so-called 1*6) with two amino acids substitutions within
its N-terminal and C-terminal transactivation domains respective-
ly. These point mutations result in constitutive STAT5 phosphor-
ylation, nuclear localization and transactivation properties [64].
Expression of constitutively active STAT5A-1*6 is sufficient to
confer IL-3-independent growth to Ba/F3 cells in vitro and
tumorigenicity to bone marrow cells in vivo [64,71]. Importantly,
Figure 3. a-Br-TMC inhibits both JAK2 and STAT5 phosphorylation. Ba/F3 cells were pre-treated 30 minutes with the indicated
concentrations of TSA and a-Br-TMC (A) or with 10 mM a-Br-TMC and DMSO vehicle (B, C) and further stimulated with 5 ng/mL IL-3 for 30 minutes
(A), 15 minutes (B) or 5 minutes (C). Final DMSO concentration was 0.02% in (A) and 0.01% in (B, C). Protein whole cell extracts (panels A, C) or
cytosolic (C) and nuclear (N) extracts (panel B) were prepared as described in Materials and Methods and analyzed by Western-blot using antibodies
specific for phospho-STAT5 (pSTAT5), phospho-JAK2 (pJAK2), STAT5A, STAT5B, STAT5A and B, JAK2 and a-tubulin (loading control and cytosolic-
specific marker). SDS-PAGE in (C) was shorter, explaining why the STAT5 mobility patterns (a-Br-TMC-induced shift and STAT5A and B doublet) are
not as apparent as on immunoblots in (A, B).
doi:10.1371/journal.pone.0090275.g003
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JAK2 is not activated in Ba/F3-1*6 cells as a consequence of IL-3-
independent growth [4,64]. The mechanism of constitutive
activation of STAT5A-1*6 is unclear. Whether basal JAK2
activity or an unidentified tyrosine kinase is responsible for
STAT5A-1*6 phosphorylation is unknown [4,64]. Increased
stability of the phosphorylated STAT5A-1*6 mutant via an
uncharacterized mechanism also contributes to its constitutive
activity [64]. The human K562 leukemia cell line expresses a
constitutively active BCR-ABL tyrosine kinase. BCR-ABL onco-
genic fusion protein constitutively phosphorylates STAT5A and
STAT5B proteins, directly contributing to oncogenesis [72–74].
Ba/F3, Ba/F3-1*6 and K562 cells were treated with 0.2 mM
TSA or 10 mM a-Br-TMC for 90 minutes, with Ba/F3 being
stimulated 60 minutes with IL-3 following 30 minute inhibitor pre-
treatment, as before. In addition, K562 cells were treated with
1 mM of the BCR-ABL specific inhibitor Imatinib, as a positive
control for inhibition of STAT5 phosphorylation [75]. Expression
of STAT5 target genes (Cis, Osm, c-Myc, Pim-1), of JAK2/MAPK-
regulated STAT5-independent genes (JunB, c-Fos), and of a
housekeeping control gene (36b4) was evaluated by quantitative
RT-PCR (Figure 5). As predicted upon expression of constitutively
active STAT5-1*6 [46], expression of the STAT5 target genes was
up-regulated in growing Ba/F3-1*6 cells in comparison to
unstimulated Ba/F3 cells (Figure 5A–B). As anticipated, expres-
sion of the STAT5 target genes in all three cell lines was inhibited
by TSA (Figure 5A–C). Similarly, STAT5 target genes were
down-regulated in Imatinib-treated K562 cells (Figure 5C).
Expression of all STAT5-target genes investigated in IL-3-
stimulated Ba/F3 cells, including Cis, Osm, c-Myc, Pim-1
(Figure 5A) as well as Spi2.1 and SOCS-1 (not shown) was inhibited
by a-Br-TMC. While expression of STAT5 target genes was
down-regulated in a-Br-TMC-treated Ba/F3 cells (Figure 5A),
distinct effects of a-Br-TMC were noted in Ba/F3-1*6 and K562
cells (Figure 5B–C). For instance, expression of Cis and Osm was
up-regulated in a-Br-TMC-treated Ba/F3-1*6 (Figure 5B) and
K562 (Figure 5C) cells. c-Myc and Pim-1 mRNA levels were
Figure 4. RNA polymerase II recruitment to the Cis and Osm promoters is impeded in Ba/F3 cells treated with a-Br-TMC. Ba/F3 cells
were pre-treated 30 minutes with 0.2 mM TSA or 10 mM a-Br-TMC before being stimulated with 5 ng/mL IL-3 for 30 minutes. DMSO (vehicle) was
adjusted to 0.02% in all conditions. Chromatin immunoprecipitation (ChIP) was performed as described in Materials and Methods using antibodies
directed against STAT5 or RNA polymerase II (RNA Pol II) proteins. Co-precipitated genomic DNA was analyzed by quantitative PCR using primers
specific for the STAT5 binding sites (STAT5 ChIP) or the transcription start site (RNA Pol II ChIP) of the mouse Cis (A) and Osm (B) genes.
doi:10.1371/journal.pone.0090275.g004
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partially reduced in a-Br-TMC-treated Ba/F3-1*6 cells
(Figure 5B), while c-Myc mRNA level was slightly increased in
a-Br-TMC-treated K562 cells (Figure 5C). Therefore, the a-Br-
29,3,4,49-tetramethoxychalcone exerts distinct effects on STAT5
target gene expression in normal Ba/F3 vs. its transformed
counterpart Ba/F3-1*6, as well as in the oncogenic K562 cell line.
Both JAK2-mediated MAPK-dependent genes JunB and c-Fos
were induced by IL-3 in Ba/F3 cells (Figure 5A). Their expression
was either unaffected or upregulated by TSA respectively, as
previously reported [46]. Expression of JunB and c-Fos was
inhibited by a-Br-TMC, probably as a consequence of JAK2
inhibition (Figure 5A). In contrast to Ba/F3 cells, JunB and c-Fos
genes were expressed at background levels in Ba/F3-1*6 cells
(Figure 5B), most likely as a result of the absence of JAK2/MAPK
activation [4]. Treatment of Ba/F3-1*6 cells with a-Br-TMC did
not affect JunB expression while c-Fos was slightly up-regulated
(Figure 5B), although mRNA levels remained low in comparison
to that detected in IL-3-stimulated Ba/F3 cells (Figure 5A). The
observation that a-Br-TMC was able to up-regulate the expression
of c-Fos - and of other genes - in Ba/F3 cells transformed with
STAT5A-1*6 but not in Ba/F3 parental cells, suggests that a-Br-
TMC might target other factor(s) involved in gene regulation in
Ba/F3-1*6 cells.
To further evaluate the effect of a-Br-TMC on normal and
transformed cells, cytotoxicity and cell viability assays were
performed as before (Figure 2A–B). The effect of a-Br-TMC on
proliferation and survival of Ba/F3-1*6 and K562 cells was
comparable to that observed with normal Ba/F3 cells. All cells
died in the presence of 5 mM a-Br-TMC, while reduced
proliferation and minimal cell death were observed in the presence
of 0.5 mM a-Br-TMC over 48 hours (Figure 2B and data not
shown). On the other hand, a-Br-TMC-induced cytotoxicity (at
100 mM) was reduced by approximately 50% in the transformed
Ba/F3-1*6 and K562 cell lines in comparison to normal Ba/F3
cells (Figure 2A; 75% cytotoxicity in Ba/F3 cells vs. 47% and 42%
in Ba/F3-1*6 and K562 cells respectively). This indicates a distinct
chemosensitivity of the cancer cell lines to a-Br-TMC. Together
with the observation that a-Br-TMC differentially affects gene
expression in the transformed cells, our results suggest that its
activity is regulated in a distinct manner in the investigated normal
vs. transformed cell lines.
In conclusion, our gene expression analysis demonstrated that
a-Br-TMC differentially regulates expression of STAT5 target
genes in normal and cancer cells. Since we showed that a-Br-
TMC hinders STAT5 transcriptional activity in Ba/F3 cells by
inhibiting both STAT5 and JAK2 phosphorylation and possibly
by modifying STAT5 proteins, we examined the effect of a-Br-
TMC on JAK2 and STAT5 proteins in the transformed Ba/F3-
1*6 and K562 cells.
a-Br-TMC-induced STAT5 protein modification
differentially modulates STAT5 activity in normal and
cancer cells
STAT5 phosphorylation in Ba/F3-1*6 and K562 cells was
assessed by Western-blot analysis as before, on cells treated with
0.4 to 10 mM a-Br-TMC or 0.2 mM TSA. Both cell lines were also
treated with 1 mM Imatinib, as a positive control for pSTAT5
inhibition in K562 cells and a negative control for Ba/F3-1*6 cells
(Figure 6A). As expected, TSA did not affect STAT5 phosphor-
ylation in Ba/F3-1*6 and K562 cells. Similarly, the BCR-ABL
inhibitor Imatinib did not affect STAT5 phosphorylation in Ba/
F3-1*6 cells, while drastically inhibiting STAT5 phosphorylation
in K562 cells, as previously reported [75]. As observed in Ba/F3
cells, treatment of Ba/F3-1*6 and K562 cells with a-Br-TMC led
to a decrease in STAT5 phosphorylation and a downward
mobility shift of both STAT5A and STAT5B proteins, in a dose-
dependent manner (Figure 6A and 6B). Again, STAT5B appeared
to be more affected than STAT5A.
We next assessed the effect of a-Br-TMC on JAK2 phosphor-
ylation in Ba/F3-1*6 and K562 cells (Figure 6B). In agreement
with previous reports [4,64], pJAK2 was barely detectable in Ba/
F3-1*6 cells. The absence of JAK2 phosphorylation in Ba/F3-1*6
cells is also in agreement with our gene expression data, revealing
only basal expression levels of the JAK2/MAPK-dependent genes
c-Fos and JunB (Figure 5B). The observation that STAT5 proteins
undergo a-Br-TMC-mediated dephosphorylation and mobility
shift in the absence of JAK2 supports the idea that these
modifications occur in a JAK2-independent manner. Finally, like
in Ba/F3 cells, JAK2 phosphorylation in K562 cells was inhibited
upon a-Br-TMC treatment (Figure 6B), further indicating that a-
Br-TMC targets both JAK2 and STAT5 proteins.
Discussion
In the search for novel STAT5 inhibitors, we examined the
effect of a series of natural and synthetic chalcones as well as of
curcumin, another natural a,b-unsaturated carbonyl compound,
on JAK2/STAT5 activation and expression of downstream
STAT5 target genes in normal (Ba/F3) and caSTAT5-trans-
formed (Ba/F3-1*6, K562) cell lines.
We show here that the synthetic a-Br-29,3,4,49-tetramethox-
ychalcone (a-Br-TMC) is a potent inhibitor of both JAK2 tyrosine
kinase and STAT5 transcription factor activities. None of the
natural products investigated (curcumin and five natural chal-
cones) affected STAT5-mediated transactivation of the Cis gene in
IL-3-stimulated Ba/F3 cells at a concentration of 20 mM. Amongst
the four synthetic chalcones a-X-TMCs (with X=CN, Br, Cl, H)
tested, a-Br-TMC was the only active STAT5 inhibitor. We
showed before that a-Br-TMC, a-Cl-TMC and to a lesser extent
a-H-TMC exhibit anti-inflammatory activities in RAW364.7 cells,
in particular inhibiting both Nrf2- and NF-kB-dependent path-
ways [59]. We could not detect an effect of a-Br-TMC on the
expression of the Nrf2-dependent Ho-1 gene in Ba/F3 cells,
possibly due to the short duration of treatment. Nevertheless,
taken together, our data indicate that a-Br-TMC is able to target
multiple pathways controlling inflammation, proliferation and
survival. The natural compound sophoraflavanone G was recently
reported to exhibit a similar pleiotropic activity against both the
JAK/STAT signaling pathway and pathways controlling inflam-
mation and infection in murine and human cell lines [36]. Since
interconversion between flavanones and 29-OH-chalcones was
recently evidenced in cell culture [76], it might explain why these
two classes of molecules exhibit similar biological activities.
In accordance with the pleiotropic activity of a-Br-TMC, we
found that it targets the JAK2/STAT5 pathway at multiple levels
(Figure 7). First, a-Br-TMC inhibits JAK2 tyrosine kinase
activation, thus indirectly inhibiting activation of pathways
downstream of JAK2, in particular STAT5 and mitogen-activated
protein kinase (MAPK). Second, a-Br-TMC inhibits constitutive
STAT5 phosphorylation in cells showing basal JAK2 activation
(Ba/F3-1*6). Although we cannot rule out that basal JAK2
activation is responsible for the constitutive STAT5 phosphory-
lation in Ba/F3-1*6 cells [4], our data suggest that a-Br-TMC also
inhibits STAT5 phosphorylation - directly or indirectly - in a
JAK2-independent manner. Third, a-Br-TMC might alter a post-
translational modification on STAT5 proteins, as revealed by a
downward mobility shift in SDS-PAGE. a-Br-TMC treatment
changed the mobility of both STAT5A and STAT5B proteins in
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SDS-PAGE, although STAT5B appears more strongly affected
than STAT5A. Moreover, this effect takes place within the
cytoplasm and independently of IL-3 stimulation and STAT5
phosphorylation. In fact, the faster-migrating STAT5 forms could
still be phosphorylated and translocated into the nucleus to some
extent. Since this protein modification correlates with a reduced
phosphorylation of STAT5A-1*6, possibly independent of JAK2,
it is tempting to speculate that a-Br-TMC-induced STAT5
modification interferes - directly or indirectly - with STAT5
activation and hence STAT5 transcriptional activity.
As a result of reduced JAK2 and STAT5 activation, transcrip-
tion of STAT5 target genes such as Cis and Osm was impaired, in
agreement with a diminished recruitment of RNA polymerase II
to their respective transcription start site. Somewhat surprisingly,
STAT5 binding to DNA was marginally diminished upon a-Br-
TMC treatment. It suggests that the modified nuclear STAT5
proteins still have the ability to bind to DNA and hence might
compete with transcriptionally competent unmodified STAT5
proteins.
We found that although STAT5 proteins were similarly
modified by a-Br-TMC in normal and transformed cells based
on their mobility profile in SDS-PAGE, the consequence on
expression of downstream target genes was different. Indeed, while
expression of Cis and Osm was down-regulated in Ba/F3 cells, it
was up-regulated in Ba/F3-1*6 and K562 cells. Meanwhile,
expression of the c-Myc oncogene was reduced in both Ba/F3 and
Ba/F3-1*6 cells but slightly increased in K562 cells. According to
the differential effect of a-Br-TMC on gene expression, the three
cell lines exhibited a distinct chemosensitivity to a-Br-TMC. These
observations suggest that a-Br-TMC might target additional
signaling and/or transcription factors in cells transformed by
constitutively active STAT5 (mouse Ba/F3-1*6 and human
K562), resulting in distinct gene expression patterns. The
observation that basal expression of c-Fos in Ba/F3-1*6 cells in
the absence of Jak2 activation was slightly increased upon a-Br-
TMC treatment would support this hypothesis. On the other
hand, we cannot exclude that a-Br-TMC-mediated modification
of STAT5 protein differentially affects STAT5 transcriptional
activity in normal and cancer cells. Given that STAT5 DNA
binding activity was only weakly impaired in a-Br-TMC-treated
cells, one could indeed envisage that DNA-bound STAT5 protein
complexes exhibit distinct transcriptional activities depending on
the cellular context. For instance, STAT5 is known to regulate
transcription through interactions with positive and negative
cofactors and with other transcription factors bound on adjacent
sites, as well as through tetramerization [1,9–11], which could be
differentially regulated in transformed cells. Clearly, additional
experiments are needed to determine whether STAT5 is also
bound to the Cis promoter in Ba/F3-1*6 and K562 cells and
further unravel the underlying molecular mechanism.
The question remains as to how a-Br-TMC inhibits JAK2
activation. We cannot rule out at this point that a-Br-TMC acts as
Figure 5. a-Br-TMC exerts distinct effects in normal and cancer cells. Ba/F3 (A), its caSTAT5-transformed counterpart Ba/F3-1*6 (B) and
human leukemic K562 (C) cells were treated 90 minutes with 0.2 mM TSA, 10 mM a-Br-TMC or 1 mM Imatinib. Ba/F3 cells (A) were stimulated with
5 ng/mL IL-3 after an initial 30 minute drug pre-treatment (hence subjected to a 60 minute IL-3 stimulation). DMSO (vehicle) final concentration was
adjusted to 0.02% in all conditions. Expression of STAT5-dependent (Cis, Osm, c-Myc, Pim-1) and -independent (JunB, c-Fos, 36b4) genes was analyzed
by quantitative RT-PCR. Gene expression data were normalized to mouse ribosomal S9 (A, B) or to human Lamin A/C (LMNA) (C) housekeeping gene-
encoded mRNAs. (A, B) Normalized data are presented with adjusted Y-axis scale for a direct comparison of mRNA levels in the respective normal
and transformed Ba/F3 and Ba/F3-1*6 cell lines.
doi:10.1371/journal.pone.0090275.g005
Figure 6. a-Br-TMC inhibits the STAT5 signaling pathway in both a JAK2-dependent and -independent manner. (A) Ba/F3-1*6 and
K562 cells were treated for 60 minutes with the indicated compounds. Protein whole cell extracts were analyzed by Western-Blot using antibodies
specific for pSTAT5, STAT5A, STAT5B, STAT5A and B and a-tubulin as a loading control. (B) Ba/F3 cells were pre-treated 30 minutes with 10 mM a-Br-
TMC and stimulated with 5 ng/mL IL-3 for 5 minutes. Ba/F3-1*6 and K562 cells were treated with 10 mM a-Br-TMC for 90 minutes. DMSO (Veh.) was
adjusted to 0.01% in all conditions. Protein whole cell extracts were analyzed by Western-Blot using antibodies specific for pSTAT5, pJAK2, STAT5A,
STAT5B, STAT5A and B, JAK2 and a-tubulin (loading control).
doi:10.1371/journal.pone.0090275.g006
Inhibition of JAK2 and STAT5 by a a-Br-Chalcone
PLOS ONE | www.plosone.org 10 March 2014 | Volume 9 | Issue 3 | e90275
a tyrosine kinase inhibitor. Indeed, its structure is reminiscent of
that of AG490, a reversible substrate competitive tyrosine kinase
inhibitor [77,78]. In addition, the nature of the protein
modification(s) targeting STAT5 upon a-Br-TMC treatment
remains to be identified. Several lines of evidences support the
idea that the divergent C-terminal transactivation domain of
STAT5 is targeted for modification, including the observations
that (i) a-Br-TMC inhibited STAT5 phosphorylation at Y694/
699, (ii) a-Br-TMC-induced mobility shift of STAT5A was not as
pronounced as that of STAT5B, (iii) a-Br-TMC differentially
modulated STAT5 transcriptional activity in normal and trans-
formed cells. On the other hand, the observation that STAT5
DNA binding activity was only slightly impaired, raises the
possibility that the STAT5 DNA binding domain might be
modified as well.
Chalcones in general, and a-Br-TMC in particular, present a
highly electrophilic a,b-unsaturated carbonyl moiety that can
potentially react with free sulfhydryl groups of cysteine residues in
proteins and directly alter their function. On the other hand,
electrophiles can inhibit the activation of transcription factors such
as NF-kB and STAT3, possibly through S-glutathionylation of
cysteine thiol groups, which is itself triggered by a rapid drop of
intracellular glutathione [55,79]. Three naturally occuring ter-
penes, which also contain an electrophilic a,b-unsaturated
carbonyl group, induce S-glutathionylation of STAT3 thereby
inhibiting its activity [80,81]. Similarly to our a-Br-TMC
compound, these molecules also inhibit the activation of JAK2
tyrosine kinase [80]. In agreement with the identification of several
essential cysteine residues within JAK2 catalytic domain [82],
activity of JAK2 - but also of STAT5 - is regulated by the synthetic
glutathione disulfide mimetic NOV-002 [83], suggesting that both
JAK2 and STAT5 can be S-glutathionylated. Finally, a review of
the literature revealed that S-glutathionylation and redox regula-
tion can either stimulate or inhibit protein activity [82,83],
possibly depending on the position of the modified cysteine within
the functional domains of the targeted protein. Altogether, these
observations raise the possibility that a-Br-TMC, as a potent
Michael acceptor, might alter the function of STAT5 and JAK2
proteins, through either direct alkylation or indirect S-glutathio-
nylation of accessible thiol groups, thereby inhibiting or stimulat-
ing their activity depending on the cellular context. The presence
of cysteine residues in STAT5 proteins, both common and unique
to STAT5A and STAT5B within their DNA binding and
transactivation domains respectively, is consistent with that model.
On the other hand, the detection of a downward mobility shift
of STAT5A and STAT5B upon a-Br-TMC treatment is not in full
agreement with the covalent addition of one or several S-
glutathione groups. Such downward shift is rather reminiscent of
protein dephosphorylation and one could envision an alternative
mode of action for a-Br-TMC. Beside tyrosine phosphorylation,
STAT5 proteins can be phosphorylated on serine residues [84].
Interestingly, STAT5A and STAT5B are differentially phosphor-
ylated on C-terminal serines (S725/730 in mSTAT5A/B; S779 in
mSTAT5A) [84], resulting in either positive or negative
transcriptional regulation depending on promoter and/or cellular
context [85,86]. It remains therefore possible that a-Br-TMC
either inhibits the still-unknown kinase responsible for serine
phosphorylation of STAT5 or activates a specific serine phospha-
tase, leading to the STAT5 mobility shift detected in SDS-PAGE
and possibly to the alteration of its activity.
Whether a-Br-TMC acts as a tyrosine kinase inhibitor and
whether the a-Br-TMC-induced STAT5 mobility shift involves S-
glutathionylation and/or dephosphorylation of STAT5 and/or of
other regulatory components of the STAT5 pathway is currently
under investigation.
In conclusion, we identified the synthetic chalcone a-Br-TMC
as a novel regulator of JAK2/STAT5 activity, targeting both
STAT5 and its upstream activating kinase JAK2 (Figure 7). Its
ability to down-regulate expression of the c-Myc oncogene while
up-regulating expression of the tumor suppressor gene Cis in
cancer cells, together with its previously described anti-inflamma-
tory properties [59], potentially makes a-Br-TMC a promising
novel therapeutic agent with pleiotropic anti-inflammatory and
anticancer activities.
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Figure 7. Model of inhibition of the JAK2/STAT5 pathway by a-
Br-TMC. IL-3 binding to the a/bc chains of the IL-3 receptor leads to
activation of the receptor-associated JAK2 tyrosine kinase by trans-
phosphorylation. In turn, JAK2-mediated activation of the STAT5, MAPK
and AKT pathways via phosphorylation (broad arrows) results in
induced transcription of downstream target genes (thin arrows). We
showed that a-Br-TMC inhibits JAK2 phosphorylation, hence impairing
JAK2-regulated signaling pathways. In addition and independently of
JAK2, a-Br-TMC inhibits STAT5 activity. Concomitantly, STAT5A and
STAT5B protein mobility in SDS-PAGE is altered, indicating a change in
their post-translational modification state induced by a-Br-TMC, which
might be associated to STAT5 altered transcriptional activity.
doi:10.1371/journal.pone.0090275.g007
Inhibition of JAK2 and STAT5 by a a-Br-Chalcone
PLOS ONE | www.plosone.org 11 March 2014 | Volume 9 | Issue 3 | e90275
References
1. Grimley PM, Dong F, Rui H (1999) Stat5a and Stat5b: fraternal twins of signal
transduction and transcriptional activation. Cytokine Growth Factor Rev 10:
131–157.
2. Wakao H, Gouilleux F, Groner B (1994) Mammary gland factor (MGF) is a
novel member of the cytokine regulated transcription factor gene family and
confers the prolactin response. EMBO J 13: 2182–2191.
3. Basham B, Sathe M, Grein J, McClanahan T, D’Andrea A, et al. (2008) In vivo
identification of novel STAT5 target genes. Nucleic Acids Res 36: 3802–3818.
4. Nosaka T, Kawashima T, Misawa K, Ikuta K, Mui AL, et al. (1999) STAT5 as a
molecular regulator of proliferation, differentiation and apoptosis in hemato-
poietic cells. EMBO J 18: 4754–4765.
5. Mui AL, Wakao H, Kinoshita T, Kitamura T, Miyajima A (1996) Suppression
of interleukin-3-induced gene expression by a C-terminal truncated Stat5: role of
Stat5 in proliferation. EMBO J 15: 2425–2433.
6. Van Nguyen T, Angkasekwinai P, Dou H, Lin F-M, Lu L-S, et al. (2012)
SUMO-specific protease 1 is critical for early lymphoid development through
regulation of STAT5 activation. Mol Cell 45: 210–221.
7. Wieczorek M, Ginter T, Brand P, Heinzel T, Kra¨mer OH (2012) Acetylation
modulates the STAT signaling code. Cytokine Growth Factor Rev 23: 293–305.
8. Ma L, Gao J, Guan Y, Shi X, Zhang H, et al. (2010) Acetylation modulates
prolactin receptor dimerization. Proc Natl Acad Sci U S A 107: 19314–19319.
9. Lin JX, Leonard WJ (2000) The role of Stat5a and Stat5b in signaling by IL-2
family cytokines. Oncogene 19: 2566–2576.
10. Shuai K (2000) Modulation of STAT signaling by STAT-interacting proteins.
Oncogene 19: 2638–2644.
11. Lin J-X, Li P, Liu D, Jin HT, He J, et al. (2012) Critical Role of STAT5
transcription factor tetramerization for cytokine responses and normal immune
function. Immunity 36: 586–599.
12. Mandal M, Powers SE, Maienschein-Cline M, Bartom ET, Hamel KM, et al.
(2011) Epigenetic repression of the Igk locus by STAT5-mediated recruitment of
the histone methyltransferase Ezh2. Nat Immunol 12: 1212–1220.
13. Litterst CM, Kliem S, Marilley D, Pfitzner E (2003) NCoA-1/SRC-1 is an
essential coactivator of STAT5 that binds to the FDL motif in the alpha-helical
region of the STAT5 transactivation domain. J Biol Chem 278: 45340–45351.
14. Pfitzner E, Ja¨hne R, Wissler M, Stoecklin E, Groner B (1998) p300/CREB-
binding protein enhances the prolactin-mediated transcriptional induction
through direct interaction with the transactivation domain of Stat5, but does
not participate in the Stat5-mediated suppression of the glucocorticoid response.
Mol Endocrinol Baltim Md 12: 1582–1593.
15. John S, Vinkemeier U, Soldaini E, Darnell JE Jr, Leonard WJ (1999) The
significance of tetramerization in promoter recruitment by Stat5. Mol Cell Biol
19: 1910–1918.
16. Ward AC, Touw I, Yoshimura A (2000) The Jak-Stat pathway in normal and
perturbed hematopoiesis. Blood 95: 19–29.
17. Valentino L, Pierre J (2006) JAK/STAT signal transduction: regulators and
implication in hematological malignancies. Biochem Pharmacol 71: 713–721.
18. Bowman T, Garcia R, Turkson J, Jove R (2000) STATs in oncogenesis.
Oncogene 19: 2474–2488.
19. Liu CB, Itoh T, Arai K, Watanabe S (1999) Constitutive activation of JAK2
confers murine interleukin-3-independent survival and proliferation of BA/F3
cells. J Biol Chem 274: 6342–6349.
20. Lord JD, McIntosh BC, Greenberg PD, Nelson BH (2000) The IL-2 receptor
promotes lymphocyte proliferation and induction of the c-myc, bcl-2, and bcl-x
genes through the trans-activation domain of Stat5. J Immunol Baltim Md 1950
164: 2533–2541.
21. Nosaka T, Kitamura T (2002) Pim-1 expression is sufficient to induce cytokine
independence in murine hematopoietic cells, but is dispensable for BCR-ABL-
mediated transformation. Exp Hematol 30: 697–702.
22. Garc¸on L, Rivat C, James C, Lacout C, Camara-Clayette V, et al. (2006)
Constitutive activation of STAT5 and Bcl-xL overexpression can induce
endogenous erythroid colony formation in human primary cells. Blood 108:
1551–1554.
23. Gesbert F, Griffin JD (2000) Bcr/Abl activates transcription of the Bcl-X gene
through STAT5. Blood 96: 2269–2276.
24. Chim C-S, Fung T-K, Cheung W-C, Liang R, Kwong Y-L (2004) SOCS1 and
SHP1 hypermethylation in multiple myeloma: implications for epigenetic
activation of the Jak/STAT pathway. Blood 103: 4630–4635.
25. He B, You L, Uematsu K, Zang K, Xu Z, et al. (2003) SOCS-3 is frequently
silenced by hypermethylation and suppresses cell growth in human lung cancer.
Proc Natl Acad Sci U S A 100: 14133–14138.
26. Niwa Y, Kanda H, Shikauchi Y, Saiura A, Matsubara K, et al. (2005)
Methylation silencing of SOCS-3 promotes cell growth and migration by
enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma.
Oncogene 24: 6406–6417.
27. Weber A, Hengge UR, Bardenheuer W, Tischoff I, Sommerer F, et al. (2005)
SOCS-3 is frequently methylated in head and neck squamous cell carcinoma
and its precursor lesions and causes growth inhibition. Oncogene 24: 6699–
6708.
28. Zhang Q, Wang HY, Marzec M, Raghunath PN, Nagasawa T, et al. (2005)
STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1
tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. Proc
Natl Acad Sci U S A 102: 6948–6953.
29. Nelson EA, Sharma SV, Settleman J, Frank DA (2011) A chemical biology
approach to developing STAT inhibitors: molecular strategies for accelerating
clinical translation. Oncotarget 2: 518–524.
30. Mu¨ller J, Sperl B, Reindl W, Kiessling A, Berg T (2008) Discovery of chromone-
based inhibitors of the transcription factor STAT5. Chembiochem Eur J Chem
Biol 9: 723–727.
31. Luo C, Laaja P (2004) Inhibitors of JAKs/STATs and the kinases: a possible
new cluster of drugs. Drug Discov Today 9: 268–275.
32. Quinta´s-Cardama A, Verstovsek S (2013) Molecular pathways: Jak/STAT
pathway: mutations, inhibitors, and resistance. Clin Cancer Res Off J Am Assoc
Cancer Res 19: 1933–1940.
33. Warsch W, Walz C, Sexl V (2013) JAK of all trades: JAK2-STAT5 as novel
therapeutic targets in BCR-ABL1+ chronic myeloid leukemia. Blood 122: 2167–
2175.
34. Hayakawa F, Sugimoto K, Harada Y, Hashimoto N, Ohi N, et al. (2013) A
novel STAT inhibitor, OPB-31121, has a significant antitumor effect on
leukemia with STAT-addictive oncokinases. Blood Cancer J 3: e166.
35. Weber A, Borghouts C, Brendel C, Moriggl R, Delis N, et al. (2013) The
inhibition of stat5 by a Peptide aptamer ligand specific for the DNA binding
domain prevents target gene transactivation and the growth of breast and
prostate tumor cells. Pharm Basel Switz 6: 960–987.
36. Kim B-H, Won C, Lee Y-H, Choi JS, Noh KH, et al. (2013) Sophoraflavanone
G induces apoptosis of human cancer cells by targeting upstream signals of
STATs. Biochem Pharmacol 86: 950–959.
37. Ma L, Clayton JR, Walgren RA, Zhao B, Evans RJ, et al. (2013) Discovery and
characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of
JAK2V617F. Blood Cancer J 3: e109.
38. Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, et al. (2011) The
STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia
cells resistant to kinase inhibitors. Blood 117: 3421–3429.
39. Nelson EA, Walker SR, Xiang M, Weisberg E, Bar-Natan M, et al. (2012) The
STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous
Leukemia Driven by FLT3 Mutations. Genes Cancer 3: 503–511.
40. Hanan EJ, van Abbema A, Barrett K, Blair WS, Blaney J, et al. (2012) Discovery
of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors. J Med
Chem 55: 10090–10107.
41. Kraus M, Wang Y, Aleksandrowicz D, Bachman E, Szewczak AA, et al. (2012)
Efficacious intermittent dosing of a novel JAK2 inhibitor in mouse models of
polycythemia vera. PloS One 7: e37207.
42. Yang J, Ikezoe T, Nishioka C, Furihata M, Yokoyama A (2010) AZ960, a novel
Jak2 inhibitor, induces growth arrest and apoptosis in adult T-cell leukemia cells.
Mol Cancer Ther 9: 3386–3395.
43. Ioannidis S, Lamb ML, Wang T, Almeida L, Block MH, et al. (2011) Discovery
of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-
3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak/Stat
pathway. J Med Chem 54: 262–276.
44. Jatiani SS, Cosenza SC, Reddy MVR, Ha JH, Baker SJ, et al. (2010) A Non-
ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation
of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition.
Genes Cancer 1: 331–345.
45. Mu¨ller J, Schust J, Berg T (2008) A high-throughput assay for signal transducer
and activator of transcription 5b based on fluorescence polarization. Anal
Biochem 375: 249–254.
46. Rascle A, Johnston JA, Amati B (2003) Deacetylase activity is required for
recruitment of the basal transcription machinery and transactivation by STAT5.
Mol Cell Biol 23: 4162–4173.
47. Rascle A, Lees E (2003) Chromatin acetylation and remodeling at the Cis
promoter during STAT5-induced transcription. Nucleic Acids Res 31: 6882–
6890.
48. Gryder BE, Sodji QH, Oyelere AK (2012) Targeted cancer therapy: giving
histone deacetylase inhibitors all they need to succeed. Future Med Chem 4:
505–524.
49. Evrot E, Ebel N, Romanet V, Roelli C, Andraos R, et al. (2013) JAK1/2 and
Pan-deacetylase inhibitor combination therapy yields improved efficacy in
preclinical mouse models of JAK2V617F-driven disease. Clin Cancer Res
Off J Am Assoc Cancer Res 19: 6230–6241.
50. Wang Y, Fiskus W, Chong DG, Buckley KM, Natarajan K, et al. (2009)
Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates
JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against
human myeloproliferative neoplastic cells. Blood 114: 5024–5033.
51. Guerini V, Barbui V, Spinelli O, Salvi A, Dellacasa C, et al. (2008) The histone
deacetylase inhibitor ITF2357 selectively targets cells bearing mutated
JAK2(V617F). Leukemia 22: 740–747.
52. Pietschmann K, Bolck HA, Buchwald M, Spielberg S, Polzer H, et al. (2012)
Breakdown of the FLT3-ITD/STAT5 axis and synergistic apoptosis induction
by the histone deacetylase inhibitor panobinostat and FLT3-specific inhibitors.
Mol Cancer Ther 11: 2373–2383.
53. Nguyen T, Dai Y, Attkisson E, Kramer L, Jordan N, et al. (2011) HDAC
inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in
Inhibition of JAK2 and STAT5 by a a-Br-Chalcone
PLOS ONE | www.plosone.org 12 March 2014 | Volume 9 | Issue 3 | e90275
imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
Clin Cancer Res Off J Am Assoc Cancer Res 17: 3219–3232.
54. Batovska DI, Todorova IT (2010) Trends in utilization of the pharmacological
potential of chalcones. Curr Clin Pharmacol 5: 1–29.
55. Liu Y-C, Hsieh C-W, Wu C-C, Wung B-S (2007) Chalcone inhibits the
activation of NF-kappaB and STAT3 in endothelial cells via endogenous
electrophile. Life Sci 80: 1420–1430.
56. Pandey MK, Sung B, Ahn KS, Aggarwal BB (2009) Butein suppresses
constitutive and inducible signal transducer and activator of transcription
(STAT) 3 activation and STAT3-regulated gene products through the induction
of a protein tyrosine phosphatase SHP-1. Mol Pharmacol 75: 525–533.
57. Funakoshi-Tago M, Tago K, Nishizawa C, Takahashi K, Mashino T, et al.
(2008) Licochalcone A is a potent inhibitor of TEL-Jak2-mediated transforma-
tion through the specific inhibition of Stat3 activation. Biochem Pharmacol 76:
1681–1693.
58. Liu Y, Gao X, Deeb D, Arbab AS, Dulchavsky SA, et al. (2012) Anticancer
agent xanthohumol inhibits IL-2 induced signaling pathways involved in T cell
proliferation. J Exp Ther Oncol 10: 1–8.
59. Al-Rifai N, Ru¨cker H, Amslinger S (2013) Opening or Closing the Lock? When
Reactivity Is the Key to Biological Activity. Chem Eur J 19: 15384–15395.
60. Amslinger S, Al-Rifai N, Winter K, Wo¨rmann K, Scholz R, et al. (2013)
Reactivity assessment of chalcones by a kinetic thiol assay. Org Biomol Chem
11: 549–554.
61. Amslinger S (2010) The tunable functionality of alpha,beta-unsaturated carbonyl
compounds enables their differential application in biological systems.
ChemMedChem 5: 351–356.
62. Lozzio CB, Lozzio BB (1975) Human chronic myelogenous leukemia cell-line
with positive Philadelphia chromosome. Blood 45: 321–334.
63. Palacios R, Steinmetz M (1985) Il-3-dependent mouse clones that express B-220
surface antigen, contain Ig genes in germ-line configuration, and generate B
lymphocytes in vivo. Cell 41: 727–734.
64. Onishi M, Nosaka T, Misawa K, Mui AL, Gorman D, et al. (1998) Identification
and characterization of a constitutively active STAT5 mutant that promotes cell
proliferation. Mol Cell Biol 18: 3871–3879.
65. Rascle A, Neumann T, Raschta A-S, Neumann A, Heining E, et al. (2009) The
LIM-homeodomain transcription factor LMX1B regulates expression of NF-
kappa B target genes. Exp Cell Res 315: 76–96.
66. Matsumoto A, Masuhara M, Mitsui K, Yokouchi M, Ohtsubo M, et al. (1997)
CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway
and modulates STAT5 activation. Blood 89: 3148–3154.
67. Elliott J, Hookham MB, Johnston JA (2008) The suppressors of cytokine
signalling E3 ligases behave as tumour suppressors. Biochem Soc Trans 36: 464–
468.
68. Fujihara M, Ikebuchi K, Maekawa TL, Wakamoto S, Ogiso C, et al. (1998)
Lipopolysaccharide-induced desensitization of junB gene expression in a mouse
macrophage-like cell line, P388D1. J Immunol Baltim Md 1950 161: 3659–
3665.
69. Santos FPS, Verstovsek S (2011) JAK2 inhibitors: what’s the true therapeutic
potential? Blood Rev 25: 53–63.
70. Paukku K, Silvennoinen O (2004) STATs as critical mediators of signal
transduction and transcription: lessons learned from STAT5. Cytokine Growth
Factor Rev 15: 435–455.
71. Schwaller J, Parganas E, Wang D, Cain D, Aster JC, et al. (2000) Stat5 is
essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2.
Mol Cell 6: 693–704.
72. De Groot RP, Raaijmakers JA, Lammers JW, Jove R, Koenderman L (1999)
STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia
cells. Blood 94: 1108–1112.
73. Nieborowska-Skorska M, Wasik MA, Slupianek A, Salomoni P, Kitamura T,
et al. (1999) Signal transducer and activator of transcription (STAT)5 activation
by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of
BCR/ABL and is required for leukemogenesis. J Exp Med 189: 1229–1242.
74. Ilaria RL Jr, Van Etten RA (1996) P210 and P190(BCR/ABL) induce the
tyrosine phosphorylation and DNA binding activity of multiple specific STAT
family members. J Biol Chem 271: 31704–31710.
75. Roskoski R Jr (2003) STI-571: an anticancer protein-tyrosine kinase inhibitor.
Biochem Biophys Res Commun 309: 709–717.
76. Simmler C, Hajirahimkhan A, Lankin DC, Bolton JL, Jones T, et al. (2013)
Dynamic residual complexity of the isoliquiritigenin-liquiritigenin interconver-
sion during bioassay. J Agric Food Chem 61: 2146–2157.
77. Levitzki A, Mishani E (2006) Tyrphostins and Other Tyrosine Kinase Inhibitors.
Annu Rev Biochem 75: 93–109.
78. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, et al. (1996) Inhibition
of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379: 645–648.
79. Xie Y, Kole S, Precht P, Pazin MJ, Bernier M (2009) S-glutathionylation impairs
signal transducer and activator of transcription 3 activation and signaling.
Endocrinology 150: 1122–1131.
80. Butturini E, Cavalieri E, de Prati AC, Darra E, Rigo A, et al. (2011) Two
naturally occurring terpenes, dehydrocostuslactone and costunolide, decrease
intracellular GSH content and inhibit STAT3 activation. PloS One 6: e20174.
81. Butturini E, de Prati AC, Chiavegato G, Rigo A, Cavalieri E, et al. (2013) Mild
oxidative stress induces S-glutathionylation of STAT3 and enhances chemo-
sensitivity of tumoral cells to chemotherapeutic drugs. Free Radic Biol Med.
82. Mamoon NM, Smith JK, Chatti K, Lee S, Kundrapu K, et al. (2007) Multiple
cysteine residues are implicated in Janus kinase 2-mediated catalysis.
Biochemistry (Mosc) 46: 14810–14818.
83. Townsend DM, He L, Hutchens S, Garrett TE, Pazoles CJ, et al. (2008) NOV-
002, a glutathione disulfide mimetic, as a modulator of cellular redox balance.
Cancer Res 68: 2870–2877.
84. Decker T, Kovarik P (2000) Serine phosphorylation of STATs. Oncogene 19:
2628–2637.
85. Yamashita H, Xu J, Erwin RA, Farrar WL, Kirken RA, et al. (1998) Differential
control of the phosphorylation state of proline-juxtaposed serine residues Ser725
of Stat5a and Ser730 of Stat5b in prolactin-sensitive cells. J Biol Chem 273:
30218–30224.
86. Beuvink I, Hess D, Flotow H, Hofsteenge J, Groner B, et al. (2000) Stat5a serine
phosphorylation. Serine 779 is constitutively phosphorylated in the mammary
gland, and serine 725 phosphorylation influences prolactin-stimulated in vitro
DNA binding activity. J Biol Chem 275: 10247–10255.
Inhibition of JAK2 and STAT5 by a a-Br-Chalcone
PLOS ONE | www.plosone.org 13 March 2014 | Volume 9 | Issue 3 | e90275
